Clinical trial
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
NCT00044018 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00044018 |
|---|---|
| Title | CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma |
| Official title | An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | CDC-501 |
| Enrollment | 102 |
| Start date | Apr 1, 2002 |
| Primary completion | Dec 1, 2004 |
| Completion | Feb 15, 2007 |
| First posted | Aug 20, 2002 |
| Last update posted | Nov 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: